Investment analysts at StockNews.com started coverage on shares of MediciNova (NASDAQ:MNOV - Get Free Report) in a research note issued on Tuesday. The firm set a "hold" rating on the biopharmaceutical company's stock.
Separately, D. Boral Capital began coverage on MediciNova in a research report on Monday, December 2nd. They issued a "buy" rating and a $9.00 price target on the stock.
Check Out Our Latest Analysis on MediciNova
MediciNova Stock Up 0.9 %
Shares of NASDAQ:MNOV traded up $0.02 during trading on Tuesday, reaching $2.13. The stock had a trading volume of 46,023 shares, compared to its average volume of 49,353. The firm has a market capitalization of $104.47 million, a price-to-earnings ratio of -10.05 and a beta of 0.84. MediciNova has a 52 week low of $1.12 and a 52 week high of $2.55. The stock has a fifty day simple moving average of $1.92 and a two-hundred day simple moving average of $1.64.
Institutional Trading of MediciNova
An institutional investor recently bought a new position in MediciNova stock. Jane Street Group LLC bought a new stake in MediciNova, Inc. (NASDAQ:MNOV - Free Report) in the 3rd quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The firm bought 14,138 shares of the biopharmaceutical company's stock, valued at approximately $30,000. Hedge funds and other institutional investors own 9.90% of the company's stock.
MediciNova Company Profile
(
Get Free Report)
MediciNova, Inc, a biopharmaceutical company, focuses on developing novel and small molecule therapeutics for the treatment of serious diseases with unmet medical needs in the United States. It is developing MN-166 (ibudilast), an oral anti-inflammatory and neuroprotective agent for treating neurological and other disorders, such as primary and secondary progressive multiple sclerosis, amyotrophic lateral sclerosis, chemotherapy-induced peripheral neuropathy, degenerative cervical myelopathy, glioblastoma, and substance dependence and addiction, as well as prevention of acute respiratory distress syndrome, and long COVID.
Featured Stories
Before you consider MediciNova, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and MediciNova wasn't on the list.
While MediciNova currently has a "Buy" rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Options trading isn’t just for the Wall Street elite; it’s an accessible strategy for anyone armed with the proper knowledge. Think of options as a strategic toolkit, with each tool designed for a specific financial task. Keep reading to learn how options trading can help you use the market’s volatility to your advantage.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
